ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO2393

Donor-Derived Cell-Free DNA Kinetics After Kidney Transplant Biopsy

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Kyeso, Yousuf, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Bhalla, Anshul, Methodist University Hospital, Memphis, Tennessee, United States
  • Smith, Alyssa P., Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Alakhdhair, Safa, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Abuzeineh, Mohammad, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Brennan, Daniel C., Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Alasfar, Sami, Johns Hopkins Medicine, Baltimore, Maryland, United States
Background

Donor-derived cell-free DNA (dd-cfDNA) has generated interest as a potential biomarker for kidney transplant (KT) rejection. It is possible that the KT biopsy procedure itself can cause the release of dd-cfDNA in the blood stream, therefore affecting the reliability of this assay in the post biopsy period. In this study we evaluated the effect of KT biopsy on the level dd-cfDNA and assessed the magnitude and duration of this effect.

Methods

We conducted a single arm prospective study. Samples were collected from 16 adult KT recipients undergoing renal allograft biopsy. All participants had samples drawn within eight hours prior to the biopsy (pre-biopsy), within 20 minutes (hour 0), 2 hours after (hour 2), and 24-48 hours (hours 24-48) after the biopsy.

Results

Mean age at the time of biopsy was 50.6 ± 7.02 years. Most participants were men and Caucasian. Mean serum creatinine at the time of biopsy was 2.24 +/- 0.42 mg/dL. The most common reason for obtaining biopsy was rise in serum creatinine, while 4 patients had the biopsy due to elevation in dd-cfDNA. The pre-biopsy time point was compared against all remaining time points. At hour 0 and hour 2, there was a significantly larger log dd-cfDNA mean scores compared to pre-biopsy time point (0.37 vs -0.44, p=0.006), (0.35 vs -0.44, p=0.03) respectively. By 24-28 hours post biopsy there was no significant difference in log dd-cfDNA mean score compared to the pre-biopsy score.

Conclusion

KT biopsy leads to an increase in dd-cfDNA percentage after the procedure, however, this rise is transient and resolves by 24-48 hour after the biopsy. Providers can obtain dd-cfDNA level as soon as 48 hours post biopsy with high confidence that the levels have not been affected by the biopsy.

Observed longitudinal Log-Transformed AlloSure Measurements by Assessment Time Point

Funding

  • Commercial Support –